Shilpa Medicare Limited, together with its subsidiaries, engages in the manufacturing and selling active pharmaceutical ingredients (APIs), finished dosage formulations, biologicals, and other allopathic pharmaceutical preparations in India, the United States, Europe, and internationally. It's primary oncology APIs include capecitabine, gemcitabine hydrochloride, pemetrexed, axitinib, erlotinib hydrochloride, and irinotecan hydrochloride; and non-oncology APIs, such as ambroxol, tranexmic acid, and ursodeoxycholic acid; as well as novel-drug delivery systems. The company provides contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, and lyophilized injectables. In addition, it is involved in manufacture of specialized oncology formulations; and wind power generation activities. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.
Screener.in
